

Match Overview

1	Internet 41 words crawled on 27-Oct-2020 www.wjgnet.com	3%
2	Crossref 34 words Jan Baan, Bimmer E. Claessen, Kirsten Boerlage-van Dijk, Jeroen Vendrik et al. "A Randomized Comparison of Pa	2%
3	Internet 31 words crawled on 05-May-2020 bmccardiovascdisord.biomedcentral.com	2%
4	Internet 24 words crawled on 13-Sep-2020 pubmed.ncbi.nlm.nih.gov	2%
5	Internet 13 words crawled on 26-Oct-2009 www.biokorea.org	1%
6	Internet 13 words crawled on 05-Oct-2019 f6publishing.blob.core.windows.net	1%

6
Name of Journal: *World Journal of Clinical Cases*

Manuscript Type: CASE REPORT

Restenosis of a Drug Eluting Stent on the Previous Bioresorbable Vascular Scaffold
Successfully Treated with a Drug-Coated Balloon: A Case Report

Running title: Jang HG, et al. Restenosis of DES on the BVS

Hyun Gyung Jang, Kyehwan Kim, Hyun Woon Park, Jin-Sin Koh, Young-Hoon Jeong,
Jeong Rang Park, Min Gyu Kang



ALL

IMAGES

VIDEOS

41,300 Results

Any time ▼

[Restenosis of Drug-Eluting Stents | Circulation ...](#)

<https://www.ahajournals.org/doi/10.1161/CIRCINTERVENTIONS.118.007023>

Jul 26, 2019 · **High rates** of in-stent restenosis (ISR) associated with bare-metal stents (BMSs) led to the development of drug-eluting stents (DESs), which modified the healing process after stent implantation, attenuating neointimal formation, and resulting in a reduction of the incidence of ISR to rates ranging from 5% to 10%. 1 Despite improvements in stent design, drugs, and polymers with modern DESs, ISR ...

Cited by: 8**Author:** Evan Shlofmitz, Micaela Iantorno, Ron W...**Publish Year:** 2019

[Recurrent drug eluting stent in-stent restenosis: A state ...](#)

<https://www.sciencedirect.com/science/article/pii/S1553838920300142>

Jan 10, 2020 · Recurrent in-stent restenosis (R-ISR) refers to the **re-occlusion** of a successfully treated in-stent restenosis. Much of the present understanding of this condition stems from studies on in-stent restenosis, as literature on R-ISR is sparse.

Author: Achintya D. Singh, Aayush K. Singal, ...**Publish Year:** 2020

[Successful treatment of recurrent carotid in-stent ...](#)



ALL

IMAGES

VIDEOS

34,200 Results

Any time ▾

Restenosis of Drug-Eluting Stents | Circulation ...

<https://www.ahajournals.org/doi/10.1161/CIRCINTERVENTIONS.118.007023>

Jul 26, 2019 · High rates of in-stent **restenosis** (ISR) associated with bare-metal stents (BMSs) led to the development of **drug-eluting** stents (DESs), which modified the healing process after **stent** implantation, attenuating neointimal formation, and resulting in a reduction of the incidence of ISR to rates ranging from 5% to 10%. 1 Despite improvements in **stent** design, drugs, and polymers with modern DESs ...

Cited by: 12

Author: Evan Shlofmitz, Micaela Iantorno, Ron Wak...

Publish Year: 2019

Repetitive restenosis in a biodegradable polymer sirolimus ...

<https://academic.oup.com/ehjcr/article/4/1/1/5722210> ▾

Feb 04, 2020 · Introduction. Hypersensitivity reaction is a classic cause of in-stent **restenosis** (ISR) in coronary stents. 1 The biodegradable polymer sirolimus-**eluting stent** (BP-SES, Ultimaster ®, Terumo Corporation, Tokyo, Japan), a new-generation **drug-eluting stent** (DES), was developed with a biodegradable polymer that was believed to suppress inflammation around the **stent** and ameliorate ...

Cited by: 1

Author: Takahiro Jimba, Takehiro Hashikata, Masa...

Publish Year: 2020

Search Tools

Turn on Hover Translation (开启取词)

激活 Windows

转到“设置”以激活 Windows。



ALL

IMAGES

VIDEOS

MAPS

NEWS

SHOPPING

33,900 Results

Any time ▾

[Restenosis of Drug-Eluting Stents | Circulation ...](#)

<https://www.ahajournals.org/doi/10.1161/CIRCINTERVENTIONS.118.007023>

Jul 26, 2019 · High rates of in-stent restenosis (ISR) associated with bare-metal stents (BMSs) led to the development of **drug-eluting** stents (DESs), which modified the healing process after **stent** implantation, attenuating neointimal formation, and resulting in a reduction of the incidence of ISR to rates ranging from 5% to 10%. 1 Despite improvements in **stent** design, drugs, and polymers with modern DESs ...

Cited by: 12

Author: Evan Shlofmitz, Micaela Iantorno, Ron Wak...

Publish Year: 2019

[Repetitive restenosis in a biodegradable polymer sirolimus ...](#)

<https://academic.oup.com/ehjcr/article/4/1/1/5722210> ▾

Feb 04, 2020 · Introduction. Hypersensitivity reaction is a classic cause of in-stent restenosis (ISR) in coronary stents. 1 The biodegradable polymer sirolimus-**eluting stent** (BP-SES, Ultimaster ®, Terumo Corporation, Tokyo, Japan), a new-generation **drug-eluting stent** (DES), was developed with a biodegradable polymer that was believed to suppress inflammation around the **stent** and ameliorate ...

Cited by: 1

Author: Takahiro Jimba, Takehiro Hashikata, Masa...

Publish Year: 2020

[Successful treatment of recurrent carotid in-stent ...](#)

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4802336>

Presentation of **case**. We hereby **report** the **case** of a patient with recurrent carotid in-stent restenosis and **drug-eluting balloon** failure **treated** with a coronary **bioresorbable vascular scaffold**, achieving a satisfactory acute and long-term result, as disclosed by duplex ultrasound scan performed more than 1 year after the procedure.

Cited by: 8

Author: Arturo Giordano, Paolo Ferraro, Nicola Corc...

Publish Year: 2016

[Recurrent Drug-Eluting Stent In-Stent Restenosis: A State ...](#)